PharmacoCheck+
Allows Clinicians to better understand how their patients will respond to certain medications.
Simple Buccal Swab-FDA
Adverse Drug Reactions (ADRs) remain one of theleading causes of morbidity and mortality in modern healthcare. Withapproximately 100,000 deaths and over 2 million serious ADRs reported annuallyin the United States alone, there is a critical need for more precise andindividualized approaches to medication management. Pharmacogenetics Testing,offered through the PharmacoCheck+ Personalized Medicine Panel, enablesclinicians to proactively assess a patient’s genetic predisposition to drugmetabolism, thereby reducing the risk of ADRs and improving therapeuticefficacy.
PharmacoCheck+ examines geneticvariants across key drug-metabolizing enzymes and transporters. By identifyingwhether a patient is a poor, intermediate, normal, or ultra-rapidmetabolizer, the test provides actionable data to guide medicationselection, dosing adjustments, and therapeutic monitoring across a wide rangeof therapeutic areas.
Pharmacogenetics has become an essential tool in the shift toward precision medicine. By incorporating genetic data into prescribing decisions, clinicians can:
* Identify the most effective medication prior to treatment initiation
* Minimize the risk of severe ADRs
* Optimize dosing to match individual metabolism
* Improve patient outcomes while reducing unnecessary healthcare costs
- PharmacoCheck+ allows clinicians to match patients with medications most likely to be effective, avoiding drugs with a higher risk for adverse effects based ongenetic predisposition.
- This evidence-based approach is especially valuable in therapeutic are as such as psychiatry, cardiology, oncology, and pain management.
- Genetic variation in drug metabolism (e.g., CYP2D6, CYP2C19)directly affects the required drug dose. PharmacoCheck+ helps determine appropriate initial dosing and adjustments over time.
- PharmacoCheck+ highlights increased risk for toxicity, therapeutic failure, or hypersensitivity reactions—enabling preemptive adjustments to therapy.
- This is especially important for high-risk medications such as anticoagulants, antipsychotics, antidepressants, and chemotherapeutic agents.
- Results become a permanent part of the patient’s medical record, supporting future prescribing decisions across multiple specialties and clinical encounters.
The genetic profile can guide lifelong personalized medication plans, improving care continuity.
* Ultra-rapid metabolizer
Faster-than-normal drug clearance, potentially reducing drug efficacy at standard doses.
* Normal metabolizer
Expected drug metabolism with standard dosing typically effective.
* Intermediate metabolizer
Slower drug clearance, requiring dose adjustments to avoid accumulation.
* Poor metabolizer
Significantly reduced enzyme function, leading to excessive drug accumulation and higher risk for ADRs.
ADRs contribute to approximately 100,000 deaths annually in theU.S.
Over 2 million serious ADRs occur each year.
Nursing homes experience 350,000 ADRs per year, adding to healthcare burden and costs.
(Source: FDA - Preventable AdverseDrug Reactions: A Focus on Drug Interactions.)
The PharmacoCheck+ Personalized Medicine Paneluses advanced Single Nucleotide Polymorphism (SNP) genotyping analysisto detect both common and rare genetic variants relevant to drugmetabolism.
* Sample Type: Buccal swab (non-invasive).
* Platform: OpenArray technology.
* Genotyping Software: TaqMan® Genotyper
* Each result meets stringent quality control metrics, ensuring call accuracy of >95%.
* CYP2D6 copy number variations (CNVs) are also assessed to ensure comprehensive evaluation of this critical pharmaco gene.
This test detects only predefined variants and does not capture all possible mutations affecting drug metabolism.
Non-genetic factors such as drug-drug interactions, organ function, and concurrent medical conditions also influence drug response.
Results should be interpreted alongside clinical history, concomitant medications, and relevant laboratory data.
This test complies with CLIA regulations but does not hold FDA approval, which is not required for this type of high-complexity testing under current guidelines.
Personalized Prescribing
Enhanced drug efficacy and reduced ADR risk.
Cost Savings
Fewer hospitalizations, reduced poly pharmacy, lower medication waste.
Patient Safety
Improved monitoring and prevention of severe drug reactions.
Lifelong Utility
One-time test supports medication decisions across future medical needs.
Pharmacogenetics testing through PharmacoCheck+empowers healthcare providers to deliver precision prescribing, reducingthe reliance on trial-and-error medication selection. By proactivelyidentifying genetic risks for ADRs and therapeutic failure, this approachsupports safer, more effective, and more cost-efficient healthcare delivery.As precision medicine continues to evolve, PharmacoCheck+ offers anindispensable tool for personalized pharmacotherapy, helping cliniciansprovide better care—tailored to the genetic uniqueness of each patient.
1: Amstutz, U. et al. Clinical PharmacogeneticsImplementation Consortium (CPIC) Guideline for Dihydropyrimidine DehydrogenaseGenotype and Fluoropyrimidine Dosing: 2017 Update. Clinical Pharmacology &Therapeutics 103, 210-216 (2017).
2: Bell, G. et al. Clinical Pharmacogenetics ImplementationConsortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron andtropisetron. Clinical Pharmacology & Therapeutics 102, 213-218 (2017).
3: Birdwell, K. et al. Clinical PharmacogeneticsImplementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and TacrolimusDosing. Clinical Pharmacology & Therapeutics 98, 19-24 (2015).
4: Brown, J. et al. Clinical PharmacogeneticsImplementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype andAtomoxetine Therapy. Clinical Pharmacology & Therapeutics 106, 94-102(2019).
5: CooperDeHoff, RM. et al. Clinical PharmacogeneticsImplementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypesand StatinAssociated Musculoskeletal Symptoms. Clinical Pharmacology &Therapeutics 111, 10071021 (2022).
6: Crews, K. et al. Clinical PharmacogeneticsImplementation Consortium (CPIC) Guideline for CYP2D6, OPRM1, and COMT genotypeand select opioid therapy. Clinical Pharmacology & Therapeutics 110,888-896 (2021).
7: Desta, Z. et al. Clinical PharmacogeneticsImplementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-ContainingAntiretroviral Therapy. Clinical Pharmacology & Therapeutics 106, 726-733(2019).
8: Dutch Pharmacogenetics Working Group. DutchPharmacogenetics Working Group Guidelines May 2020. (2020).
9: Gammal RS. et al. Clinical PharmacogeneticsImplementation Consortium Guideline for Medication Use in the Context of G6PDGenotype. Clinical Pharmacology & Therapeutics 113, 973-985 (2022).
10: Gammal, RS. et al. Clinical PharmacogeneticsImplementation Consortium (CPIC) Guideline for UGT1A1 and AtazanavirPrescribing. Clinical Pharmacology & Therapeutics 99, 363-369 (2016).
11: Goetz M. et al. Clinical PharmacogeneticsImplementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.Clinical Pharmacology & Therapeutics 103, 770-777 (2018).
12: Gonsalves, SG. et al. Clinical PharmacogeneticsImplementation Consortium (CPIC) Guideline for the Use of Potent VolatileAnesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1SGenotypes. Clinical Pharmacology & Therapeutics 105, 1338-1344 (2019).
13: Ham, A. et al. CYP2C9 Genotypes ModifyBenzodiazepine-Related Fall Risk: Original Results From Three Studies WithMeta-Analysis. Journal of the American Medical Directors Association 18,88.e1-88.e15 (2017).
14: He, W. et al. CYP2D6 genotype predicts tamoxifendiscontinuation and drug response: a secondary analysis of the KARISMA trial.Annals of Oncology 32, 1286-1293 (2021).
15: Hicks, J. et al. Clinical PharmacogeneticsImplementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes andDosing of Selective Serotonin Reuptake Inhibitors. Clinical Pharmacology &Therapeutics 98, 127-134 (2015).
16: Hicks, J. et al. Clinical pharmacogeneticsimplementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes anddosing of tricyclic antidepressants: 2016 update. Clinical Pharmacology &Therapeutics 102, 37-44 (2017).
17: Johnson, J. et al. Clinical PharmacogeneticsImplementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided WarfarinDosing: 2017 Update. Clinical Pharmacology & Therapeutics 102, 397-404(2017).
18: Karnes, J. et al. Clinical pharmacogeneticsimplementation consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes andphenytoin dosing: 2020 update. Clinical Pharmacology & Therapeutics 109,302-309 (2021).
19: King, D. et al. Smoking cessation pharmacogenetics:analysis of varenicline and bupropion in placebo-controlled clinical trials.Neuropsychopharmacology 37, 641-650 (2012).
20: Lee, C. et al. Clinical Pharmacogenetics ImplementationConsortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.Clinical Pharmacology & Therapeutics 112, 959-967 (2022).
21: Lerman, C. et al. Use of the nicotine metabolite ratioas a genetically informed biomarker of response to nicotine patch orvarenicline for smoking cessation: a randomised, double-blindplacebo-controlled trial. The Lancet Respiratory Medicine 3, 131-138 (2015).
22: Lima, J. et al. Clinical PharmacogeneticsImplementation Consortium (CPIC) Guideline for CYP2C19 and Proton PumpInhibitor Dosing. Clinical Pharmacology & Therapeutics (2020)
23: Lipworth, J. et al. Tailored second-line therapy inasthmatic children with the Arg(16) genotype. Clinical science 124, 521-528(2013).
24: Martin, MA. et al. Clinical pharmacogeneticsimplementation consortium guidelines for HLA-B genotype and abacavir dosing.Clinical Pharmacology & Therapeutics 91, 734-738 (2012).
25: McDermott, JH. et al. Clinical PharmacogeneticsImplementation Consortium Guideline for the Use of Aminoglycosides Based onMT-RNR1 Genotype. Clinical Pharmacology & Therapeutics 111, 366-372 (2022).
26: Moriyama, B. et al. Clinical PharmacogeneticsImplementation Consortium (CPIC) Guidelines for CYP2C19 and VoriconazoleTherapy. Clinical Pharmacology & Therapeutics 102, 45-51 (2017).
27: Muir, A. et al. Clinical PharmacogeneticsImplementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEGInterferon-alpha-Based Regimens. Clinical Pharmacology & Therapeutics 95,141-146 (2014).
28: Novartis Pharmaceuticals Corporation. Promacta ProductMonograph. 10 (2018).
29: Phillips, E. et al. Clinical PharmacogeneticsImplementation Consortium Guideline for HLA Genotype and Use of Carbamazepineand Oxcarbazepine: 2017 Update. Clinical Pharmacology & Therapeutics 103,574-581 (2018).
30: Relling, M. et al. Clinical PharmacogeneticsImplementation Consortium Guideline for Thiopurine Dosing Based on TPMT andNUDT15 Genotypes: 2018 Update. Clinical Pharmacology & Therapeutics 105,1095-1105 (2019).
31: Saito, Y. et al. Clinical PharmacogeneticsImplementation Consortium (CPIC) guidelines for human leukocyte antigen B(HLA-B) genotype and allopurinol dosing: 2015 update. Clinical Pharmacology& Therapeutics 99, 36-37 (2015).
32: Theken, K. et al. Clinical PharmacogeneticsImplementation Consortium (CPIC) Guideline for CYP2C9 and NonsteroidalAntiinflammatory Drugs. Clinical Pharmacology & Therapeutics 108, 191-200(2020)
33: Ueta, M. et al. Independent strong association ofHLAA*02:06 and HLAB*44:03 with cold medicinerelated StevensJohnson syndromewith severe mucosal involvement. Scientific Reports 4, 4862 (2014).
34: Ueta, M. et al. Transethnic study confirmed independentassociations of HLAA*02:06 and HLAB*44:03 with cold medicinerelatedStevensJohnson syndrome with severe ocular surface complications. ScientificReports 4, 5981 (2014).
35: US Food and Drug Administration. Table ofPharmacogenetic Associations. (2020).
36: Vijverberg, S. et al. Arg16 ADRB2 genotype increasesthe risk of exacerbations in children with a reported use of beta-2 agonists:Results of the PACMAN cohort study. Pharmaceutisch Weekblad 150, 233-238(2015).
37: Wakamatsu, T. et al. Human Leukocyte Antigen Class IGenes Associated With Stevens-Johnson Syndrome and Severe Ocular ComplicationsFollowing Use of Cold Medicine in a Brazilian Population. JAMA Ophthalmology135, 355 (2017).
38: Wechsler, M. et al. Effect of beta2-adrenergic receptorpolymorphism on response to longacting beta-agonist in asthma (LARGE trial): agenotype-stratified, randomised, placebo-controlled, crossover trial. TheLancet 374, 1754-1764 (2009).
latest announcements and stay updated on our most recent developments.
.svg)
